title: Relationship between FTC 'tar' and urine mutagenicity in smokers of tobacco-burning or Eclipse cigarettes.
abstract: The US Federal Trade Commission (FTC) classifies domestic cigarettes into one of three 'tar' categories based on 'tar' and nicotine levels. The objective of the present study was to determine urine mutagenicity in groups of smokers of ultra-low 'tar' (ULT), full-flavor low 'tar' (FFLT) and full-flavor 'tar' (FF) filtered cigarettes after switching to primarily tobacco-heating Eclipse cigarettes. Sixty-seven smokers maintained a specified diet and consumed ad libitum their usual brands of cigarettes, switched to Eclipse, and switched back to their usual brands. Twenty-four hour urine samples were collected weekly, concentrated on XAD-2 resin, and tested in the Ames mutagenicity assay using bacterial strains TA98 and YG1024 with S9 metabolic activation. Daily consumption of cigarettes was not significantly different (at P<0.05) between FTC 'tar' categories and average daily cigarette consumption did not change significantly in any smoker group after switching to Eclipse cigarettes. Average urine mutagenicity was 47% less (P<0.05) for ULT than for FFLT usual brand smokers as measured by the more sensitive strain YG1024, although no significant differences (P<0.05) were observed in urine mutagenicity between usual brand FTC 'tar' categories as measured by strain TA98. The reduction in urinary mutagens in the more sensitive strain, YG1024, observed in ULT smokers as compared with higher 'tar' categories suggest reduced exposure to mutagens. Usual brand salivary cotinine in the ULT group was significantly lower (P<0.05) than the FF group and the FFLT group. Salivary cotinine did not differ significantly (at P<0.05) among the smoker groups when smoking Eclipse compared to usual brand. After switching to Eclipse, the following reductions in urinary mutagenicity were observed: ULT, 70.1+/-6.4% (TA98), 70.9+/-6.2% (YG1024); FFLT, 77.1+/-2.4% (TA98), 73.6+/-2.0% (YG1024); and FF, 76.1+/-3.5% (TA98), 71.4+/-4.0% (YG1024). Across all 'tar' categories, cigarette smokers experienced significant reductions (P<0.05) in urine mutagenicity, but not salivary cotinine, upon switching to Eclipse. The reduction in urine mutagenicity when smoking Eclipse provides supporting evidence that Eclipse may present less risk of cancer compared to cigarettes currently in the market.
authors.affiliation: R. J. Reynolds Tobacco Company, Research and Development, Product Evaluation Group, Winston-Salem, NC 27102, USA. bomand5@rjrt.com
authors.forename: Denise L
authors.initials: DL
authors.lastname: Bowman
authors.forename: Carr J
authors.initials: CJ
authors.lastname: Smith
authors.forename: Betsy R
authors.initials: BR
authors.lastname: Bombick
authors.forename: Jerry T
authors.initials: JT
authors.lastname: Avalos
authors.forename: Riley A
authors.initials: RA
authors.lastname: Davis
authors.forename: Walter T
authors.initials: WT
authors.lastname: Morgan
authors.forename: David J
authors.initials: DJ
authors.lastname: Doolittle
mesh_terms: D003367:Cotinine / Q000032:analysis; D005260:Female; D006801:Humans; D008297:Male; D009152:Mutagenicity Tests / Q000379:methods; D012463:Saliva / Q000378:metabolism; D012907:Smoking / Q000009:adverse effects* / Q000652:urine*; D013638:Tars / Q000009:adverse effects* / Q000145:classification; D014026:Nicotiana
chemical_list: D013638:Tars; C024746:tobacco tar; D003367:Cotinine